NEW YORK – DDL-920 Reversing the Symptoms of Alzheimer's Disease could mark a significant breakthrough in the treatment of this debilitating condition. While current therapies primarily focus on targeting the physical manifestations of Alzheimer's, such as amyloid plaques, a new approach is emerging. Rather than concentrating on combating the plaques associated with Alzheimer's disease, researchers
LONDON - Artificial intelligence has developed a treatment for an aggressive form of cancer in just 30 days and demonstrated it can predict a patient's survival rate using doctors' notes. The breakthroughs were performed by separate systems, but show how the powerful technology's uses go far beyond the generation of images and text. University of Toronto
CANTON - MMS Holdings, a data-focused contract research organization – announced its partnership with the Institute for Advanced Clinical Trials to accelerate the development of life-saving therapeutics, including vaccines, medicines, and medical devices for children. MMS is a sponsor of I-ACT’s Spin Challenge, a creative way to raise funds to advance and accelerate children’s clinical
Artificial Intelligence and Big Data will be the two most impactful technologies for the pharmaceutical industry for the fourth year in a row in 2023, according to a survey by GlobalData. The leading data and analytics company notes that 39 percent of healthcare industry professionals in the survey believed that AI would be the emerging
ANN ARBOR - Michigan's biosciences industry statewide grew 22 percent in 2021 to include 2,429 companies. The information is contained in Biotechnology Innovation Organization tenth biennial report “The U.S. Bioscience Industry: Fostering Innovation and Driving America’s Economy Forward” with new employment and economic impact data (through 2021) for the nation’s biosciences industry The report, produced
LIVONIA — Hygieia, a provider of digital therapeutics for insulin management, has added Metro Detroit Endocrinology Center in Dearborn as a clinical partner. The partnership extends Hygieia’s d-Nav network and makes autonomous insulin therapy service available for underserved populations. The unique d-Nav Insulin Management Program uses AI-powered technology to prescribe the appropriate insulin dose each
DETROIT - Recently, a tiny group of people with rectal cancer saw their disease vanish after experimental treatment. It was a very small trial done by doctors at New York's Memorial Sloan Kettering Cancer Center, wherein the patients took a drug called dostarlimab for six months. At the end of their trial, every single one of their
NEW YORK - In what appears to be a very promising breakthrough for the treatment of rectal cancer, a small drug trial conducted in the US found every patient treated in the experiment had their cancer successfully go into remission. The medication given, called dostarlimab and sold under the brand name Jemperli, is an immunotherapy drug used
CANTON – MMS Holdings – a data-focused CRO – announced this week the addition of Kevin Chartier, Ph.D., as Principal Advisor of Biostatistics and Submissions Planning. Chartier will work with the biostatistics team across MMS global operations to support Sponsors with complex studies and submissions. Bringing more than 25 years of statistics experience, Chartier has held positions at Astellas Pharma, Novartis, Wyeth, Pfizer, and United BioSource Corporation across
ANN ARBOR—The pharmaceutical firm Esperion Therapeutics Inc. feported a rise in sales of its novel cholesterol-reducing drugs in the second quarter ended June 30 but still posted a loss as efforts to boost the drug’s sales continue. The company posted a loss of $43.7 million or $1.67 a share in the quarter, compared to net
